Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04884399
Other study ID # CMAB818-I-001
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date June 3, 2021
Est. completion date December 22, 2022

Study information

Verified date March 2024
Source Shanghai Biomabs Pharmaceutical Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double-blind, two-group parallel, positive-controlled clinical Phase I trial comparing the safety, pharmacokinetics, pharmacodynamics and efficacy of CMAB818 and Lucentis® in patients with wet age-related macular degeneration.


Description:

This is a phase I, randomized, double-blind, two-group parallel, positive-controlled clinical trial at four sites. Subjects will be sequentially enrolled according to the protocol in one of two cohorts and receive a single 0.5mg of CMAB818 or Lucentis® through intravitreal injection. The primary objective is to assess the initial clinical safety of intravitreal injection of CMAB818 or Lucentis® in patients with wet age-related macular degeneration (wet-AMD). The secondary objective are to assess immnogenicity, pharmacokinetic, pharmacodynamics and the initial clinical efficacy of intravitreal injection of CMAB818 or Lucentis® in patients with wet age-related macular degeneration (wet-AMD).


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date December 22, 2022
Est. primary completion date December 22, 2022
Accepts healthy volunteers No
Gender All
Age group 50 Years to 80 Years
Eligibility Inclusion Criteria: 1. Sign the informed consent, and able to receive follow-up according to the time stipulated by the trial; 2. 50 years=age=80 years, male or female; 3. The target eye must meet the following requirements: newly occurring or relapsed subfoveal and perifoveal active choroidal neovascularization (CNV) lesions secondary to AMD; the best corrected visual acuity between 78-19 letters (including the boundary value, using Early Treatment of Diabetic Retinopathy Study (ETDRS) charts, equivalent to Snellen visual acuity of 20/32 to 20/400); no refractive media opacity or myosis affecting fundus examination; 4. The best corrected visual acuity of the subject's non-target eye=19 letters (using ETDRS charts, equivalent to Snellen visual acuity of 20/400). Exclusion Criteria: 1. Previously received anti-VEGF drug treatment in either eye within 3 months before screening (e.g., aflibercept<Eylea®>, ranibizumab<Lucentis®>, bevacizumab<Avastin®>, Conbercept<Lumitin®>, etc.); 2. Active eye infection in either eye within 1 months before screening (including but not limited to Blepharitis, Conjunctivitis infective, Keratitis, Scleritis, Endophthalmitis); 3. History of vitreous hemorrhage within 3 months before screening; 4. History or presence of uncontrolled glaucoma (defined as intraocular pressure(IOP)>25 mmHg despite treatment with maximal medical therapy),or the optic fovea/optical disc ratio of the target eye caused by severe glaucoma > 0.8; 5. Previously received subconjunctival/intravitreal corticosteroids injection within 3 months (including subconjunctival/intravitreal long-acting implants within 6 months), or local ocular corticosteroids treatment in the target eye within 1 month before screening; 6. Previously received the following ophthalmic surgery such as verteporfin photodynamic therapy (PDT), macular translocation, glaucoma filtering, subfoveal laser photocoagulation, vitrectomy and transpupillary thermotherapy, and other submacular surgery or surgery used to treat age-related macular degeneration in the target eye; 7. Other ocular diseases other than wAMD that affect the central vision, such as dry AMD, venous occlusion, uveitis, diabetic retinopathy, vascular-like streaks, pathological myopia, retinal detachment, macular hole, etc. in the target eye; 8. Aphakia (excluding intraocular lenses) or rupture of the posterior lens capsule in the target eye [except for yttrium aluminum garnet (YAG) laser posterior capsulotomy after intraocular lens implantation]; 9. History of rhegmatogenous retinal detachment or macular hole retinal detachment (stage 3 or 4), with retinal detachment, retinal pigment epithelial tear, or retinal traction in the macular area and epiretinal disease in the macular area in the target eye; 10. Current use or may need to use systemic drugs that can cause crystal toxicity, such as psoralen, risedronate sodium, tamoxifen, etc.; 11. Allergy to fluorescein sodium or indocyanine green, protein products for treatment or diagnosis, and more than 2 drugs and/or non-drugs; 12. History of surgical operations (except for minimally invasive surgery that has healed) or currently unhealed wounds, moderate to severe ulcers, fractures, etc. within 1 month before screening; 13. Presence of infectious diseases that require oral, intramuscular or intravenous administration; 14. Presence of active diffuse intravascular coagulation or obvious bleeding tendency or abnormal coagulation function before screening (prothrombin time = 3 seconds of upper limit of normal value, activated partial thromboplastin time = 10 seconds of upper limit of normal value); 15. History of myocardial infarction, cerebral infarction, unstable angina, coronary revascularization, New York College of Cardiology (NYHA) grade = grade II cardiac insufficiency, severely unstable ventricular arrhythmia, and cerebrovascular accident (including transient ischemic attack) before screening; 16. Presence of systemic immune diseases (including but not limited to systemic lupus erythematosus, immune hemolytic anemia, hyperthyroidism); 17. Uncontrolled hypertension(defined assystolic blood pressure=160 mmHg and/or diastolic blood pressure=100 mmHg diastolic despite treatment with antihypertensive drugs; 18. Diabetes with uncontrolled blood glucose (defined as fasting blood glucose=7.0 mmol/L); 19. Any uncontrollable clinical problems (including but not limited to serious mental, neurological, respiratory and other system diseases, as well as malignant tumors); 20. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) higher than 1.5 times the laboratory upper limit of normal (ULN) and/or blood creatinine is higher than ULN and the investigator judges that the abnormality has clinical significance; 21. Concurrent with hepatitis B (positive hepatitis B virus surface antigen), hepatitis C (positive hepatitis C virus antibody), AIDS (positive human immunodeficiency virus antibody) or syphilis (positive syphilis antibody); 22. Pregnant and lactating women; 23. Refuse to take effective contraceptive measures during childbearing age throughout the study period; 24. Participated in any drug (excluding vitamins and minerals) and medical device clinical trials within 3 months before screening (if the drug has a long half-life and its 5 half-life time is greater than 3 months, then choose the 5 half-life time); 25. Any other situations that investigator thinks the subject is inappropriate to participate in this study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CMAB818
vascular endothelial growth factor (VEGF) inhibitor
Lucentis®
vascular endothelial growth factor (VEGF) inhibitor

Locations

Country Name City State
China Beijing Tongren Hospital Beijing Beijing
China Peking University People'S Hospital Beijing Beijing
China Shanghai General Hospital Shanghai Shanghai
China Renmin Hospital of Wuhan University Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Biomabs Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Adverse Events That Are Related to Treatment An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant graded according to the common terminology criteria for adverse events (CTCAE) v.5.0 criteria, including clinically-significant changes in physical examinations, laboratory safety tests, ECG and vital signs 0~42 days
Secondary Number of Participants With anti-drug antibody Blood samples were collected at the following time point: pre-dose, D14, D28, and D42 0~42 days
Secondary Percentage of neutralizing antibody Subjects with a positive antibody response to ranibizumab were determined to test neutralizing antibody 0~42 days
Secondary AUC(0-t) Blood samples were collected to measure the area under the concentration time curve from time 0 to last time 0~42 days
Secondary Cmax Blood samples were collected to measure maximum concentration 0~42 days
Secondary CL Blood samples were collected to measure clearance rate 0~42 days
Secondary Half-life (t1/2) Blood samples were collected to measure half-life time 0~42 days
Secondary Pharmacodynamics The plasma VEGF concentration from baseline were measured 0~42 days
Secondary Mean change in best corrected visual acuity (BCVA) from baseline BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visualacuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient 0~42 days
Secondary Mean change in central retinal thickness from baseline Central retinal thickness was measured using the Optical Coherence Tomography 0~42 days
Secondary Mean change in lesion area from baseline The lesion area was measured using Fundus Fluorescein Angiography 0~42 days
Secondary Mean change in leakage area from baseline The leakage area was measured using Fundus Fluorescein Angiography 0~42 days
See also
  Status Clinical Trial Phase
Completed NCT00138632 - Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD) Phase 1/Phase 2
Terminated NCT04594681 - A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration Phase 1
Completed NCT03585556 - AAVCAGsCD59 for the Treatment of Wet AMD Phase 1
Completed NCT03362190 - ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD) Phase 2
Not yet recruiting NCT04564937 - The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD) Phase 1/Phase 2
Recruiting NCT04504123 - MMP-9 Inhibition for Recalcitrant Wet AMD Phase 2
Terminated NCT02005133 - A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics N/A
Completed NCT01016873 - INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD Phase 2
Completed NCT03748784 - ADVM-022 Intravitreal Gene Therapy for Wet AMD Phase 1
Recruiting NCT04468997 - The Study of Drug 601 in Patients With Wet Age-related Macular Degeneration (wAMD) Phase 1
Completed NCT04685369 - Effectiveness of Anti-VEGF Treatments in Wet AMD in Active Smokers
Enrolling by invitation NCT04932980 - Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD N/A
Recruiting NCT05297292 - A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD Phase 2/Phase 3
Completed NCT03939767 - Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease
Completed NCT03066258 - Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial Phase 1/Phase 2
Terminated NCT01086761 - Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration Phase 1
Recruiting NCT05727397 - Efficacy and Safety of RC28-E Versus Aflibercept Phase 3
Completed NCT04964089 - A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) Phase 3
Withdrawn NCT01339949 - Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV) N/A
Terminated NCT00139282 - A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration Phase 3